Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02821507
Other study ID # COSYMO
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2014
Est. completion date December 2021

Study information

Verified date April 2022
Source Leiden University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is poor. New treatment options being evaluated and mouse models show in vivo that mammilian target of rapamycin (mTOR) inhibition can prevent tumour growth. mTOR is an kinase that is present in two complexes and thereby activates multiple pathways. Aberrant mTOR signalling is known to be involved in cancer cell survival. Several clinical studies for patients with bone or soft tissue sarcoma treated with mTOR inhibitors have been conducted and they show promising results. From these studies the investigators can conclude that the combination of an mTOR inhibitor with cyclophosphamide shows promising results in chondrosarcoma. With the lack of other treatment options for unresectable and metastatic chondrosarcoma or myxoid liposarcoma the Eurosarc consortium (www.eurosarc.eu) decided to treat these patients in a standardised way according to a common protocol with the combination of sirolimus and cyclophosphamide using the growth modulation index for evaluation in the current clinical study protocol.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologically proven conventional chondrosarcoma - Or pathologically proven myxoid liposarcoma with PIK3CA mutation or Phosphatase and tensin homolog (PTEN) loss - Or pathologically proven mesenchymal or dedifferentiated chondrosarcoma - Patient is 18 years and up - Documented radiographic progression of disease according to RECIST 1.1 criteria in last 6 months - Written signed informed consent - Adequate bone marrow function (Hb = 6.0 mmol/L, absolute neutrophil count = 1.5 x 109/L, platelets = 80 x 109/L) - Availability of archival tumor material for central review or be able to perform a 3 core fresh biopsy - Ability to adhere to the study visits and all protocol requirements Exclusion Criteria: - Previously treated with an mTOR inhibitor - Known to be allergic to cyclophosphamide - Life expectancy of less than 3 months - No measurable lesions according to RECIST 1.1 - Eastern cooperative oncology group (ECOG) Performance status >2 - Major surgery less than 4 weeks prior to start of treatment - Known human immunodeficiency virus (HIV) positivity - A decreased renal function with calculated glomerular filtration rate (GFR) < 30ml/min - Systemic anti-cancer therapy within 28 days prior to the first dose of study drug , or radiotherapy to a target lesion within 21 days prior to the first dose of study drug - Pregnant or lactating women - Other invasive malignancies diagnosed within the last 5 years, except non-melanoma skin cancer and localised cured prostate and cervical cancer

Study Design


Intervention

Drug:
sirolimus and cyclophosphamide


Locations

Country Name City State
Netherlands LUMC Leiden
Spain Hospital de Sant Pau Barcelona
Spain Hospital Val d'Hebron Barcelona
Spain CIO Clara Campal Madrid
Spain Hospital Universitario Virgen del Rocío Sevilla
Spain Hospital Universitario y Politécnico de La Fe Valencia
Spain Instituto Valenciano de Oncología Valencia

Sponsors (1)

Lead Sponsor Collaborator
Leiden University Medical Center

Countries where clinical trial is conducted

Netherlands,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The time to progression after start of treatment combination treatment of sirolimus and cyclophosphamide 16 weeks
Secondary Comparing pre-treatment tumor material and tumor material taken during treatment using immunohistochemistry to compare activation of the pS6, Bcl-2 and mTor pathway and DNA analysis for taqman analysis to search for hotspot mutations. 8 weeks
Secondary Register adverse events to evaluate the patient safety and tolerability of the sirolimus and cyclophosphamide combination in myxoid liposarcoma and chondrosarcoma every 8 weeks until progression (average of 1 year)
Secondary To evaluate the response according to response evaluation criteria in solid tumors (RECIST) 1.1 every 8 weeks until progression (average of 1 year)
Secondary Using the growth modulation index (GMI) to evaluate treatment efficiency GMI: Time to progression during sirolimus/cyclophosphamide treatment (TTP2) divided by time to progression before start of this treatment TTP1 every 8 weeks until progression (average of 1 year)
Secondary The overall survival after start of treatment till death every 8 weeks until progression (average of 1 year)
See also
  Status Clinical Trial Phase
Terminated NCT01957709 - Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Early Phase 1
Active, not recruiting NCT03600649 - Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Phase 1
Withdrawn NCT03397186 - Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Phase 2
Active, not recruiting NCT03989596 - Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Phase 2
Recruiting NCT04699292 - International Prospective Registry on Local Treatment Approaches in MLS
Enrolling by invitation NCT05266196 - A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Phase 1/Phase 2
Recruiting NCT05492682 - START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer Phase 1
Active, not recruiting NCT03651375 - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Phase 2
Active, not recruiting NCT00633165 - Brostallicin Clinical Trial for Myxoid Liposarcoma Phase 2
Recruiting NCT04044768 - Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Phase 2
Active, not recruiting NCT03816475 - Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial) Phase 2